We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.25
Bid: 47.00
Ask: 47.50
Change: 0.50 (1.04%)
Spread: 0.50 (1.064%)
Open: 47.75
High: 48.50
Low: 46.25
Prev. Close: 48.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Aug 2020 09:30

RNS Number : 7832V
Avacta Group PLC
11 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Avacta Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

PREMIER MITON GROUP PLC

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/08/2020

6. Date on which issuer notified (DD/MM/YYYY):

07/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.66%

N/A

4.66%

249,155,721

Position of previous notification (if

applicable)

8.13%

N/A

8.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYYW9G87

11,609,794

4.66%

SUBTOTAL 8. A

11,609,794

4.66%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Premier Miton Group Plc

Premier Asset Management Midco Ltd

Premier Asset Management Holdings Ltd

Premier Asset Management Limited

Premier Investment Group Ltd

Premier Fund Managers Ltd

4.66%

4.66%

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Please note that with effect from 27th April 2020 all investment management related activities for the Premier Miton Group plc will be carried out by Premier Fund Managers Limited. Miton Asset Management Limited and Miton Trust Managers Limited have ceased to carry out regulated activities.

 

Place of completion

LONDON, UK

Date of completion

07/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMZGMRRMRGGZG
Date   Source Headline
9th Apr 20245:00 pmRNSAvacta Reports Data at the AACR Annual Meeting
8th Apr 20247:00 amRNSAVA6000 Abstract Release by AACR
28th Mar 20244:00 pmRNSInvestor Webinar
21st Mar 20247:00 amRNSUpdate on AVA6000 Phase 1a Clinical Trial Progress
18th Mar 20241:26 pmRNSResult of General Meeting
6th Mar 20247:00 amRNSAvacta Announces AVA6000 Poster at AACR
5th Mar 20247:00 amRNSResult of REX Retail Offer
29th Feb 20247:00 amRNSResult of Placing
28th Feb 20244:42 pmRNSProposed REX Retail Offer
28th Feb 20244:41 pmRNSProposed Fundraise to progress Therapeutics
16th Feb 20247:00 amRNSShare Incentive Plan/Issue of Equity
22nd Jan 202410:51 amRNSIssue of Equity and Total Voting Rights
19th Jan 20247:00 amRNSAppointment of Christina Coughlin
19th Dec 20237:00 amRNSAppointment of Chief Business Officer
13th Dec 20237:00 amRNSALS-6000-101 Phase 1a Study Data
4th Dec 20237:00 amRNSShareholder update to review AVA6000 Phase 1a data
27th Oct 20237:00 amRNSBlock Listing Six Monthly Return
23rd Oct 20231:30 pmRNSIssue of Equity and Total Voting Rights
18th Oct 20231:00 pmRNSBlock Listing Application to AIM
5th Oct 20237:00 amRNSAvacta to present at AACR-NCI-EORTC conference
28th Sep 20237:00 amRNSInterim Results for the Period Ending 30 June 2023
20th Sep 20232:00 pmRNSIssue of Equity and Total Voting Rights
20th Sep 20237:01 amRNSPeel Hunt Appointed as Joint Broker
20th Sep 20237:00 amRNSAppointment Dr.Christina Coughlin as a consultant
19th Sep 20237:00 amRNSSuccessful Completion of Sixth Dose Escalation
6th Sep 20237:00 amRNSNotice of Results
21st Jul 20233:00 pmRNSIssue of Equity and Total Voting Rights
28th Jun 202311:00 amRNSResult of Annual General Meeting
28th Jun 20237:00 amRNSAnnual General Meeting and Shareholder Event
21st Jun 20237:00 amRNSCompletion of Fifth Dose Escalation in AVA6000
19th Jun 20237:01 amRNSDirector Appointment
19th Jun 20237:00 amRNSStatement regarding market speculation
8th Jun 20237:00 amRNSAGM and Shareholder Event Detailed Agenda
5th Jun 20237:00 amRNSSecond Milestone in AffyXell Joint Venture
2nd Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSAvacta acquires Coris Bioconcept
27th Apr 20237:00 amRNSBlock Listing Six Monthly Return
27th Apr 20237:00 amRNSFirst Patient Dosed in the US in AVA6000 Phase 1
25th Apr 20237:00 amRNSPreliminary Results
21st Apr 20232:49 pmRNSIssue of Equity and Total Voting Rights
17th Apr 20237:00 amRNSAVA3996 data poster presented at AACR
6th Apr 20237:00 amRNS1st US Clinical Investigator AVA6000 Sites Opened
5th Apr 20237:00 amRNSFirst Patient Dosed in Fifth Cohort of AVA6000
3rd Apr 20237:00 amRNSNotice of Results and Investor Presentation
27th Mar 20237:00 amRNSAVA3996 data poster presentation at AACR
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day
13th Feb 20237:00 amRNSIssue of Equity and Total Voting Rights
23rd Jan 202312:20 pmRNSIssue of Equity and Total Voting Rights
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.